Findings

What do systematic reviews say?

748 questions · 782 findings · 58 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 164 · 21%GRADE not reported 26 · 3.3%Very low 151 · 19.3%Low 222 · 28.4%Moderate 158 · 20.2%High 61 · 7.8%

Summary of findings: Protein supplements vs no intervention

Acute and late GI toxicity (grade 2+) · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Protein supplements vs no intervention

Diarrhoea (grade 2+) · People undergoing RT for pelvic cancer

It is very uncertain whether summary of findings: Protein supplements changes diarrhoea (grade 2+) compared with no intervention (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.53 [0.27, 1.03]
1 study · 74 participants
Very low

Summary of findings: Protein supplements vs no intervention

QoL · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probiotics vs placebo or control

Mean GI symptom scores · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probiotics vs placebo or control

Acute and late GI toxicity (grade 2+) · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Incidence of GTN (including low‐quality studies) · women with a molar pregnancy

The intervention may leads to lower incidence of GTN (including low‐quality studies) (low certainty).

1 finding from 1 review

Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia 2017 · Cochrane Headline outcomes only
RR 0.37 [0.24, 0.57]
3 studies · 550 participants
Low

Intervention not reported

Incidence of GTN (excluding low‐quality studies) · women with a molar pregnancy

The intervention may leads to lower incidence of GTN (excluding low‐quality studies) (low certainty).

1 finding from 1 review

Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia 2017 · Cochrane Headline outcomes only
RR 0.28 [0.1, 0.73]
1 study · 59 participants
Low

Intervention not reported

Time to GTN diagnosis (days) · women with a molar pregnancy

The intervention may leads to higher time to GTN diagnosis (days) (low certainty).

1 finding from 1 review

Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia 2017 · Cochrane Headline outcomes only
MD 28.72 [13.19, 44.24]
2 studies · 33 participants
Low

Intervention not reported

Overall survival · people with non‐rhabdomyosarcoma soft tissue sarcoma

The intervention showed no clear difference in overall survival (high certainty).

1 finding from 1 review

Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
HR 1.26 [0.7, 2.29]
1 study · 83 participants
High

Intervention not reported

Treatment‐related mortality · people with non‐rhabdomyosarcoma soft tissue sarcoma

1 finding from 1 review

Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
High

Intervention not reported

Disease‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma

The review found no eligible studies for this question.

1 finding from 1 review

Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma

The intervention showed no clear difference in progression‐free survival (high certainty).

1 finding from 1 review

Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
HR 1.34 [0.81, 2.2]
1 study · 83 participants
High

Intervention not reported

Non‐hematologic toxicity grade 3 to 4 · people with non‐rhabdomyosarcoma soft tissue sarcoma

The review found no eligible studies for this question.

1 finding from 1 review

Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma

The review found no eligible studies for this question.

1 finding from 1 review

Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Overall survival · Women with newly diagnosed epithelial ovarian cancer

The intervention leads to lower overall survival (high certainty).

1 finding from 1 review

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
HR 0.81 [0.72, 0.9]
8 studies · 2026 participants
High

Intervention not reported

hearing loss · Women with newly diagnosed epithelial ovarian cancer

The intervention leads to lower hearing loss (high certainty).

1 finding from 1 review

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
RR 0.67 [0.46, 0.99]
3 studies · 1009 participants
High

Intervention not reported

Progression‐free survival · Women with newly diagnosed epithelial ovarian cancer

The intervention leads to lower progression‐free survival (high certainty).

1 finding from 1 review

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
HR 0.78 [0.7, 0.86]
5 studies · 1311 participants
High

Intervention not reported

Severe adverse effects (G3/4) outcomes · Women with newly diagnosed epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

fever · Women with newly diagnosed epithelial ovarian cancer

The intervention leads to higher fever (high certainty).

1 finding from 1 review

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
RR 1.64 [1.13, 2.38]
5 studies · 1797 participants
High

Intervention not reported

fatigue · Women with newly diagnosed epithelial ovarian cancer

The intervention leads to higher fatigue (high certainty).

1 finding from 1 review

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
RR 2.32 [1.06, 5.07]
3 studies · 1171 participants
High